MaxCyte Inc (MXCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MaxCyte Inc (MXCT) has a cash flow conversion efficiency ratio of -0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.46 Million) by net assets ($180.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MaxCyte Inc net asset quality index to measure how much of total assets are equity-financed.
MaxCyte Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how MaxCyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MXCT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
MaxCyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MaxCyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Viet Nam Power Development JSC
VN:VPD
|
N/A |
|
Berenson Acquisition Corp I
NYSE MKT:BACA
|
1.396x |
|
Yew Lee Pacific Group Berhad
KLSE:0248
|
0.009x |
|
Barbeque Nation Hospitality Limited
NSE:BARBEQUE
|
0.243x |
|
BMT Co. Ltd
KQ:086670
|
0.008x |
|
Anixa Biosciences Inc
NASDAQ:ANIX
|
-0.132x |
|
Micware Co., Ltd. American Depositary Shares
NASDAQ:MWC
|
N/A |
|
Telechips Inc
KQ:054450
|
0.019x |
Annual Cash Flow Conversion Efficiency for MaxCyte Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of MaxCyte Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see MXCT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $206.25 Million | $-27.61 Million | -0.134x | -43.31% |
| 2023-12-31 | $232.17 Million | $-21.69 Million | -0.093x | -60.47% |
| 2022-12-31 | $253.97 Million | $-14.78 Million | -0.058x | -43.29% |
| 2021-12-31 | $262.90 Million | $-10.68 Million | -0.041x | +84.63% |
| 2020-12-31 | $33.23 Million | $-8.78 Million | -0.264x | +59.16% |
| 2019-12-31 | $13.60 Million | $-8.80 Million | -0.647x | +24.21% |
| 2018-12-31 | $12.28 Million | $-10.49 Million | -0.854x | -72.92% |
| 2017-12-31 | $19.60 Million | $-9.68 Million | -0.494x | -7.51% |
| 2016-12-31 | $5.08 Million | $-2.33 Million | -0.459x | -884.44% |
| 2015-12-31 | $-3.08 Million | $-180.50K | 0.059x | -94.99% |
| 2014-12-31 | $-1.65 Million | $-1.93 Million | 1.169x | +223.42% |
| 2013-12-31 | $-1.54 Million | $-557.80K | 0.361x | -89.96% |
| 2012-12-31 | $-590.70K | $-2.13 Million | 3.599x | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more